Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A single amino acid residue defines the difference in ovalicin sensitivity between type I and II methionine aminopeptidases.

The Journal of biological chemistry - 5 Mar 2004

Brdlik Cathleen M, Crews Craig M

Abstract excerpt

TNP-470, the first anti-angiogenic small molecule to enter clinical trials, targets methionine aminopeptidase-2 (MetAP-2), a metalloprotease that cleaves the N-terminal methionine of proteins. Previously, biochemical binding, in vivo yeast studies, and structural studies of human methionine aminopeptidase-2 bound to TNP-470 and its analogs fumagillin and ovalicin revealed that these compounds exhibit specificity...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alanine
Share to Aminopeptidases
Share to Antibiotics, Antineoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclohexanes

Share to Drug Resistance

Share to Metalloendopeptidases

Share to Sequence Alignment

Share to Sesquiterpenes

Source

Open in PubMed Open full text

Identifiers

PMID: 14676204
DOI: 10.1074/jbc.M307246200
PMCID: PMC2556556

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A single amino acid residue defines the difference in ovalicin sensitivity between type I and II methionine aminopeptidases.PMID 14676204Read ↗

The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2Semantic proximity Read ↗

The anti-angiogenic agent fumagillin covalently modifies a conserved active-site histidine in the Escherichia coli methionine aminopeptidaseSemantic proximity Read ↗

The Development of MetAP-2 Inhibitors in Cancer TreatmentSemantic proximity Read ↗

Methionine aminopeptidases and angiogenesisSemantic proximity Read ↗

Methionine aminopeptidase‑2 is a pivotal regulator of vasculogenic mimicrySemantic proximity Read ↗

Targeting methionine aminopeptidase 2 in cancer, obesity, and autoimmunitySemantic proximity Read ↗

Advances in Bacterial Methionine Aminopeptidase InhibitionSemantic proximity Read ↗

Elucidation of the function of type 1 human methionine aminopeptidase during cell cycle progressionSemantic proximity Read ↗

MetAP1 and MetAP2 drive cell selectivity for a potent anti-cancer agent in synergy, by controlling glutathione redox state.Semantic proximity Read ↗

A chemical and genetic approach to the mode of action of fumagillin.Semantic proximity Read ↗

Targeted gene disruption of methionine aminopeptidase 2 results in an embryonic gastrulation defect and endothelial cell growth arrest.Semantic proximity Read ↗

Fumagillin inhibits growth of the enteric protozoan parasite Entamoeba histolytica by covalently binding to and selectively inhibiting methionine aminopeptidase 2Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.